Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Evommune, Inc.NYSE: EVMN
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity turns positive
Q1 FY2026 total equity was $304.56M, compared with -$158.24M a year earlier.
Context
- Total equity amounted to 94.4% of total assets at the end of Q1 FY2026, down 188.0 pp from a year earlier.
- Total equity increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +292.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 205.57M USD
- Year-over-year change
- +242.5%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 205.57M | +242.5% |
| FY2024 | 2024-12-31 | (144.24M) | -85.6% |
| FY2023 | 2023-12-31 | (77.71M) | — |
Total Equity vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 total equity of $304.56M is the 3rd highest of the 10 companies compared; the peer median is $230.47M.
- Its year-over-year change of +292.5% is the highest of 10, against a peer median of -19.3%.
- Total equity amounts to 94.4% of total assets for EVMN, versus a peer median of 80.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $967.52M | +16.8% | +19.4% | 44.3% | |
FTREFortrea Holdings Inc. | Jun 2026 | $524.2M | -11.0% | -44.8% | 19.3% |
EVMNEvommune, Inc. | Mar 2026 | $304.56M | +292.5% | — | 94.4% |
| Mar 2026 | $262.65M | -4.0% | -7.9% | 89.4% | |
| Sep 2026 | $258.25M | -19.3% | -18.3% | 22.0% | |
| Mar 2026 | $230.47M | -22.8% | +47.0% | 80.0% | |
CLYMClimb Bio, Inc. | Mar 2026 | $148.09M | -23.4% | +7.6% | 97.2% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $87.85M | -48.0% | — | 82.9% |
| Mar 2026 | $43.23M | -12.9% | -29.6% | 33.4% | |
| Mar 2026 | -$265.65M | -29.0% | — | 202.1% | |
| Peer median (excluding EVMN) | $230.47M | -19.3% | -7.9% | 80.0% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.